These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 16770316

  • 1. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
    Coso D, Sebban C, Boulat O, Biron P, Rey J, Aurran T, Chabannon C, Xerri L, Chetaille B, Esterni B, Ivanov V, Stoppa AM, Schiano de Collela JM, Gastaut JA, Maraninchi D, Bouabdallah R.
    Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316
    [Abstract] [Full Text] [Related]

  • 2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 3. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
    Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM, Gruppo Italiano Terapie Innovative nei Linfomi.
    Leukemia; 2007 Aug; 21(8):1802-11. PubMed ID: 17554382
    [Abstract] [Full Text] [Related]

  • 4. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T, Raida L, Faber E, Vondrakova J, Prochazka V, Kubova Z, Skoumalova I, Jarosova M, M LK, Paucek B, Myslivecek M, Neoral C, Oral I, Jarkovsky J, Dusek L, Indrak K.
    Neoplasma; 2008 Aug; 55(3):215-21. PubMed ID: 18348654
    [Abstract] [Full Text] [Related]

  • 5. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, Kneba M, Trumper L, Loeffler M, Pfreundschuh M, Glass B, German High-Grade Non Hodgkin's Lymphoma Study Group (DSHNHL).
    Cancer; 2006 Jan 01; 106(1):136-45. PubMed ID: 16331635
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
    Cairoli R, Grillo G, Tedeschi A, Gargantini L, Marenco P, Tresoldi E, Barbarano L, Nosari AM, Morra E.
    Bone Marrow Transplant; 2002 Mar 01; 29(6):473-7. PubMed ID: 11960265
    [Abstract] [Full Text] [Related]

  • 7. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
    Hirose A, Yamane T, Nakajima Y, Manabe M, Kanashima H, Hagihara K, Sakamoto E, Nakamae M, Terada Y, Kosaka S, Aoyama Y, Sakamoto C, Kumura T, Koh KR, Hirai M, Ohta K, Nakao Y, Mugitani A, Teshima H, Hino M.
    Gan To Kagaku Ryoho; 2005 Dec 01; 32(13):2059-64. PubMed ID: 16352929
    [Abstract] [Full Text] [Related]

  • 8. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
    Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM.
    Cancer; 2006 Dec 15; 107(12):2826-32. PubMed ID: 17099879
    [Abstract] [Full Text] [Related]

  • 9. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.
    Dilhuydy MS, Lamy T, Foussard C, Gressin R, Casassus P, Deconninck E, Le Maignan C, Damotte D, Milpied N, Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Biol Blood Marrow Transplant; 2010 May 15; 16(5):672-7. PubMed ID: 20045738
    [Abstract] [Full Text] [Related]

  • 10. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
    Hess G, Flohr T, Huber C, Kolbe K, Derigs HG, Fischer T.
    Bone Marrow Transplant; 2003 May 15; 31(9):775-82. PubMed ID: 12732884
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of primary mediastinal large B-cell lymphomas].
    Schneider T, Tóth E, Molnár Z, Várady E, Deák B, Horváth A, Horváth GI, Eid H, Schneider K, Lovey J, Keresztes S, Esik O, Lengyel Z, Rosta A.
    Orv Hetil; 2004 Dec 12; 145(50):2531-7. PubMed ID: 15662753
    [Abstract] [Full Text] [Related]

  • 12. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
    Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A.
    J Clin Oncol; 2008 Jul 01; 26(19):3166-75. PubMed ID: 18490650
    [Abstract] [Full Text] [Related]

  • 13. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK, Lymphoma Study Division of the Korean Cancer Study Group.
    Ann Hematol; 2006 Apr 01; 85(4):257-62. PubMed ID: 16416337
    [Abstract] [Full Text] [Related]

  • 14. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
    Vitolo U, Liberati AM, Cabras MG, Federico M, Angelucci E, Baldini L, Boccomini C, Brugiatelli M, Calvi R, Ciccone G, Genua A, Deliliers GL, Levis A, Parvis G, Pavone E, Salvi F, Sborgia M, Gallo E, Intergruppo Italiano Linfomi.
    Haematologica; 2005 Jun 01; 90(6):793-801. PubMed ID: 15951292
    [Abstract] [Full Text] [Related]

  • 15. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.
    García-Suárez J, Bañas H, Arribas I, De Miguel D, Pascual T, Burgaleta C.
    Br J Haematol; 2007 Jan 01; 136(2):276-85. PubMed ID: 17233819
    [Abstract] [Full Text] [Related]

  • 16. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM.
    J Clin Oncol; 2005 Aug 01; 23(22):5027-33. PubMed ID: 15955905
    [Abstract] [Full Text] [Related]

  • 17. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO).
    Eur J Haematol; 2008 Mar 01; 80(3):227-35. PubMed ID: 18088400
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, PETHEMA, GELTAMO, GELCAB and GESIDA Groups.
    Br J Haematol; 2008 Feb 01; 140(4):411-9. PubMed ID: 18162120
    [Abstract] [Full Text] [Related]

  • 19. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
    Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E, Lazzarino M.
    Haematologica; 2006 Apr 01; 91(4):496-502. PubMed ID: 16537117
    [Abstract] [Full Text] [Related]

  • 20. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
    Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ.
    J Clin Oncol; 2006 Jul 01; 24(19):3121-7. PubMed ID: 16754935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.